These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 7515393)
1. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. Pincus SH; Messer KG; Nara PL; Blattner WA; Colclough G; Reitz M J Clin Invest; 1994 Jun; 93(6):2505-13. PubMed ID: 7515393 [TBL] [Abstract][Full Text] [Related]
2. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products. Akerblom L; Nara P; Dunlop N; Putney S; Morein B Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967 [TBL] [Abstract][Full Text] [Related]
3. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Kang CY; Luo L; Wainberg MA; Li Y Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338 [TBL] [Abstract][Full Text] [Related]
4. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034 [TBL] [Abstract][Full Text] [Related]
5. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081 [TBL] [Abstract][Full Text] [Related]
6. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection. Pincus SH; Messer KG; Hu SL J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780 [TBL] [Abstract][Full Text] [Related]
7. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663 [TBL] [Abstract][Full Text] [Related]
8. Correlation of maternal cytophilic human immunodeficiency virus (HIV)-1 V3 loop peptide-specific antibodies in infants with vertical HIV transmission. Wang XP; Oyaizu N; Pahwa S Pediatr Res; 1995 Sep; 38(3):384-9. PubMed ID: 7494664 [TBL] [Abstract][Full Text] [Related]
9. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694 [TBL] [Abstract][Full Text] [Related]
10. Use of the presence of anti-protein gag antibodies as an evolution marker of HIV infection. Neguţ EA; Usein CR; Sfartz S; Zugun-Eloae F Roum Arch Microbiol Immunol; 1999; 58(2):131-46. PubMed ID: 11845452 [TBL] [Abstract][Full Text] [Related]
11. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203 [TBL] [Abstract][Full Text] [Related]
12. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins. Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration. D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019 [TBL] [Abstract][Full Text] [Related]
14. Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells. Ota A; Bautista AN; Yadav ML; Ueda S Hybridoma; 1999 Apr; 18(2):139-47. PubMed ID: 10380013 [TBL] [Abstract][Full Text] [Related]
15. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120. Kang CY; Hariharan K; Posner MR; Nara P J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944 [TBL] [Abstract][Full Text] [Related]
16. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide. Ota A; Tanaka-Taya K; Ueda S Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014 [TBL] [Abstract][Full Text] [Related]
17. Variability of human immunodeficiency virus type 2 (hiv-2) infecting patients living in france. Damond F; Apetrei C; Robertson DL; Souquière S; Leprêtre A; Matheron S; Plantier JC; Brun-Vézinet F; Simon F Virology; 2001 Feb; 280(1):19-30. PubMed ID: 11162815 [TBL] [Abstract][Full Text] [Related]
18. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection. Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667 [TBL] [Abstract][Full Text] [Related]
19. [Blood antigens and specific anti-core and anti-envelope antibodies as markers of the course of HIV infection]. Sorice F; Vullo V; Cirelli A; Catania S; Mastroianni CM; Contini C; Delia S Boll Ist Sieroter Milan; 1989; 68(2):115-21. PubMed ID: 2562362 [TBL] [Abstract][Full Text] [Related]
20. Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients. Broliden PA; Morfeldt-Månsson L; Rosen J; Jondal M; Wahren B Clin Exp Immunol; 1989 May; 76(2):216-21. PubMed ID: 2503275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]